Robert C.C. Mercer

Leveraging the dominant-negative effect of the kuru-protective G127Vprion protein variant as a novel therapeutic strategy

This paper demonstrates that the G127V prion protein variant can prevent and suppress prion infection through a dominant-negative effect, suggesting its potential as a therapeutic strategy.

Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs

The paper identifies prion synaptotoxic pathways and inhibitory drugs using phosphoproteomic and transcriptomic data from prion-treated neurons.

Membrane-anchored PrPSc is the trigger for prion synaptotoxicity

This paper investigates the role of membrane-anchored PrPSc in prion-induced synaptotoxicity and shows that preventing its formation reduces synaptic damage.

Lysosomal Enhancement Prevents Infection with PrPSc, α-Synuclein & Tau Prions

This paper identifies elacridar as a compound that prevents prion infection by enhancing lysosomal function, showing effects against PrPSc, α-synuclein, and tau prions.

NMDA receptor misalignment in iPSC-derivedneurons from a multi-generational family withinherited Creutzfeldt-Jakob disease

This study uses iPSC-derived neurons from a family with the E200K prion mutation to model disease-relevant phenotypes, including PrP accumulations and NMDA receptor misalignment.

Sigma receptor ligands are potent anti-prion compounds that act independently of sigma receptor binding

The paper identifies sigma receptor ligands as potent anti-prion compounds that are effective regardless of sigma receptor binding.